Skip to content

Gene therapy

Elevidys: gene therapy for Duchenne muscular dystrophy

Elevidys is a one-time gene therapy that delivers instructions to muscle cells to produce micro-dystrophin. It is not a complete cure: the possible benefit, eligibility, and risks for each child are assessed by a specialized medical team.

Lukian Snitynskyi у світлому худі дивиться в камеру

Elevidys in brief

Four facts to understand the therapy in a minute.

What it is
gene therapy
How it is given
one-time infusion
Who it is for
patients who meet medical criteria
Why timing matters
preserved muscle function matters

What Elevidys is

Elevidys (delandistrogene moxeparvovec) is a gene therapy for people with a confirmed mutation in the DMD gene that causes Duchenne muscular dystrophy. The treatment uses the AAVrh74 viral vector to deliver genetic instructions to muscle cells so they can produce a shortened form of dystrophin: micro-dystrophin.

It is a one-time intravenous infusion, not a daily medicine. It does not remove the genetic cause of the disease forever and does not guarantee the same result for every child.

Official FDA information about Elevidys

How Elevidys treatment works

The specific pathway is defined by the specialized clinic. It usually includes four sequential steps.

  1. Diagnosis confirmation

    A genetic test must confirm a mutation in the DMD gene.

  2. Additional examinations

    The team assesses the child’s condition, liver status, immune markers, and other criteria.

  3. Elevidys administration

    The therapy is given once intravenously in a specialized center.

  4. Monitoring after therapy

    After the infusion, tests, medication support, and regular monitoring are required.

What is known about Elevidys effectiveness

Elevidys studies evaluate micro-dystrophin production and changes in motor function. Some patients showed stabilization or improvement in specific motor measures, but response to therapy can vary.

Elevidys is not considered a complete cure for Duchenne and cannot guarantee the return of already lost muscle function. The expected benefit and risks for a specific child are assessed by the medical team.

FDA indications and materials

Elevidys safety, side effects, and risks

Gene therapy requires careful patient selection and ongoing medical monitoring. Known risks include acute liver injury, immune reactions, reduced platelet count, heart muscle inflammation, and other complications.

In November 2025, the FDA added its strictest warning about the risk of acute serious liver injury and acute liver failure, and limited the U.S. indication to ambulatory patients.

Before and after infusion, doctors monitor laboratory values and prescribe the necessary support. A treatment decision must not be made without consulting a specialized team.

Current FDA warning dated November 14, 2025

Who Elevidys gene therapy may be suitable for

Under current U.S. FDA indication, Elevidys is intended for ambulatory patients aged 4 and older with a confirmed mutation in the DMD gene. The clinic also checks liver status, infections, previous vaccinations, antibody levels to the viral vector, and other medical criteria.

Eligibility rules may differ by country and medical center. The final decision on whether therapy is possible is made by doctors after a full examination.

Current FDA indication

Why timing matters

Duchenne progresses, so preserved function matters

  • The disease progresses

    Duchenne gradually weakens muscles and motor ability.

  • Lost function does not fully return

    Therapy does not guarantee recovery of functions the disease has already taken.

  • For Lukian, timely action matters

    The fundraiser should give the family a chance to undergo evaluation and organize treatment without losing time.

How much Elevidys costs and why the therapy is so expensive

The family’s fundraising goal About $2.9 million

The amount covers the medicine and the related medical pathway:

  • Medicine
  • Examinations
  • Procedure
  • Monitoring

The final estimate depends on the clinic, country, examinations, and medical support. For one family, this amount is impossible without the support of many people.

Elevidys for Lukian Snitynskyi

Lukian is 4 years old. His diagnosis has been confirmed, and his family is raising funds for treatment abroad. Read more about the family’s path on Lukian Snitynskyi’s story.

You can support the fundraiser in a convenient way, review fundraiser transparency and documents confirming the diagnosis.

Frequently asked questions

  • Does Elevidys need to be taken continuously, or is it a one-time therapy?

    It is a one-time intravenous infusion. At the same time, examinations, medication support, and regular medical monitoring are required before and after administration.

  • Does Elevidys completely cure Duchenne muscular dystrophy?

    No. Elevidys is not considered a complete cure and does not guarantee recovery of already lost function. The goal of therapy is to influence the course of the disease, but results may vary.

  • Why is Elevidys treatment not done in Ukraine?

    The medicine is not registered for use in Ukraine. Treatment is organized in specialized centers abroad that have the necessary experience and monitoring protocols.

  • How long does Elevidys treatment take, and what happens after the infusion?

    The medicine itself is given once. Preparation and follow-up monitoring take longer: doctors monitor tests, liver condition, immune response, and the child’s overall well-being.

Help Lukian receive Elevidys

Help the family raise funds for the medicine, examinations, procedure, and medical support.

Donate